The Fort Worth Press - Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress

USD -
AED 3.672498
AFN 64.999798
ALL 82.324126
AMD 360.439737
ANG 1.790403
AOA 917.999825
ARS 1543.774978
AUD 1.480635
AWG 1.8
AZN 1.699363
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.686902
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42842
CDF 2315.00023
CHF 0.840095
CLF 0.025417
CLP 1000.480332
CNY 6.67175
CNH 6.66782
COP 3316.61
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.18975
DJF 178.554905
DKK 6.790305
DOP 60.996961
DZD 137.014347
EGP 53.649023
ERN 15
ETB 164.576405
EUR 0.90831
FJD 2.280098
FKP 0.756558
GBP 0.75785
GEL 2.590074
GGP 0.756558
GHS 11.756648
GIP 0.756558
GMD 74.000006
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.84665
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 331.23032
IDR 18267.95
ILS 3.22225
IMP 0.756558
INR 93.92255
IQD 1520.102326
IRR 1913737.523681
ISK 124.069717
JEP 0.756558
JMD 158.434973
JOD 0.70902
JPY 159.523499
KES 130.039569
KGS 87.449397
KHR 4119.418691
KMF 447.000366
KPW 900.00035
KRW 1335.070061
KWD 0.31151
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.90096
MMK 2099.568705
MNT 3604.028735
MOP 8.103614
MRU 40.552456
MUR 47.809885
MVR 15.396662
MWK 1738.739965
MXN 18.573803
MYR 4.093898
MZN 63.899938
NAD 16.951268
NGN 1347.489819
NIO 36.903315
NOK 9.600095
NPR 151.114437
NZD 1.81263
OMR 0.384508
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.963967
PKR 277.274459
PLN 4.00014
PYG 6223.068898
QAR 3.655265
RON 4.859302
RSD 106.818993
RUB 82.553706
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.770647
SDG 601.516238
SEK 10.079445
SGD 1.2891
SHP 0.752984
SLE 23.050274
SLL 20969.503664
SOS 573.051087
SRD 37.49018
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.901027
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.392297
TTD 6.806306
TWD 32.943501
TZS 2651.477006
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25764
VUV 120.719595
WST 2.810584
XAF 595.812425
XAG 0.021002
XAU 0.000258521515
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 595.812425
XPF 108.186074
YER 236.549829
ZAR 16.951101
ZMK 9001.197322
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.084233
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Applied DNA Reports First Quarter Fiscal 2025  Financial Results and Highlights Operational Progress
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress

Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress

- Announces Exit of DNA Tagging and Security Products and Services Business Segment -

- Workforce Reduction of 20% of Headcount Implemented in January -

- GMP Site 1 Facility Complete and Certified for Commercial Operation in January -

- Webcast and Conference Call Scheduled for today at 4:30 PM ET -

Text size:

STONY BROOK, NY / ACCESS Newswire / February 13, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its first quarter of fiscal 2025 ended December 31, 2024. The Company's Form 10-Q, once filed, can be viewed on the SEC Filings page of its Investor Relations website.

Recent Corporate and Operational Updates:

Corporate:

  • In December 2024, the Company announced a strategic restructuring of its business operations, including the potential divestiture of its DNA Tagging and Security Products and Services ("DNA Tagging") business segment.

  • Today, the Company announced its exit from its DNA Tagging business segment and completion of a workforce reduction of approximately 20% of its total headcount related primarily to employees within its DNA Tagging segment. The workforce reduction will result in an approximate 13% reduction in annual payroll costs, offset by one-time separation costs totaling approximately $300,000, which are expected to be recorded in the quarter ending March 31, 2025. The Company will continue to service certain of its existing DNA Tagging customer contracts.

LineaRx (Therapeutic DNA Production and Services subsidiary)

  • The buildout of the Company's initial GMP facility located in Stony Brook, New York ("Site 1"), was completed on January 31, 2025, and certified for commercial operation with ISO 7-compliant with ISO 5-compliant workspaces. As currently configured, Site 1 enables the enzymatic manufacture of Linea DNA™ IVT templates used in the production of mRNA clinical trial materials:

    • The initial projected manufacturing capacity of Site 1 is approximately ten grams per annum, which supports potential annual revenues in the range of $10 million to $30 million, depending on product mix[1].

    • Site 1 gives the Company the new ability to service clients across all customer product stages with relevant grades of DNA: RUO for research and development; GLP for discovery and early pre-clinical studies; GMP for late pre-clinical studies and clinical phases.

  • The Company is in the late stage of process development with a U.S.-based therapeutics developer. If development is completed successfully, the Company anticipates its receipt of a first GMP order for IVT templates in the quarter ending June 30, 2025.

  • The Company's Linea DNA platform secured its first-in-human clinical validation with Linea DNA used as a critical component in the manufacture of a CAR-T therapy under a Czech Republic State Institute for Drug Control-approved Phase I clinical trial sponsored by the Institute of Hematology and Blood Transfusion (UHKT). The trial represents the first instance of regulatory consent of Linea DNA's use in a clinical setting and demonstrates Linea DNA's ability to empower faster manufacturing timelines than conventional plasmid DNA-based therapy development.

[1] Based on internal Company data and modeling.

Applied DNA Clinical Labs (MDx Testing Services subsidiary)

  • Completed certifications necessary to expand the TR8™ PGx testing service to all U.S. States that recognize New York's CLEP/CLIA certification for genetic testing. Samples collected from outside of New York State will be tested at Applied DNA's diagnostic laboratory in Stony Brook.

Management Commentary

"Our first quarter performance reflects the implementation of a strategic restructuring to support our growth through our synthetic DNA manufacturing strategy," stated Dr. James A. Hayward, Chairman and CEO of Applied DNA. "We are taking difficult but necessary steps to optimize our corporate structure to lower our cash burn rate and stabilize our financial position to ensure our ability to execute against near-term operational goals."

"As we move through fiscal 2025, we are focused on commercializing the DNA production capacity of our recently certified GMP Site 1 facility," concluded Dr. Hayward. "We are preparing for initial orders of clinical grade materials, the acquisition of which we believe will validate the economics of our proprietary low-CAPEX approach to enzymatic DNA production in front of an industry that is actively seeking cell-free, synthetic alternatives to traditional pDNA production processes. We believe our capacity for the GMP production of DNA in an economical, fast, and scalable manner to advance the rapid development of genetic medicines is a unique competitive advantage in the marketplace and is the lynchpin to our future success."

First Quarter Fiscal 2025 Financial Highlights

  • Total revenues:$1.2 million, an increase of 34% compared to $891 thousand for the first quarter of fiscal 2024.

  • Operating loss:$3.0 million, compared to an operating loss of $3.8 million for the first quarter of fiscal 2024.

  • Net loss: $2.7 million, compared to a net loss of $1.1 million for the first quarter of fiscal 2024.

  • Adjusted EBITDA: improved to negative $2.9 million, compared to negative $3.2 million for the first quarter of fiscal 2024.

  • Cash and cash equivalents as of December 31, 2024: $9.3 million, which includes $5.7 million of net proceeds (after deducting placement agent fees and other offering expenses) from the registered direct offering that closed on October 31, 2024.

February 13 Investor Update Conference Call Information

The Company will hold a conference call and webcast to update investors on its restructuring and GMP roadmap on February 13, 2025, at 4:30 PM ET. To participate in the conference call, please follow the instructions below. While every attempt will be made to answer investors' questions on the Q&A portion of the call, not all questions may be answered.

To participate, please ask to be joined to the 'Applied DNA Sciences' call:

  • Domestic callers (toll free): 844-887-9402

  • International callers: 412-317-6798

  • Canadian callers (toll free): 866-605-3852

  • Live and replay of webcast: link

Telephonic replay (available 1 hour following the conclusion of the live call through February 20, 2025):

  • Domestic callers (toll free): 1-877-344-7529

  • Canadian callers (toll free): 1-855-669-9658

  • Participant Passcode: 7896562

An accompanying slide presentation that will be embedded in the webcast can be accessed under 'News & Events' tab and 'Company Events' section of the Applied DNA investor relations website at https://investors.adnas.com/

Information about Non-GAAP Financial Measures

As used herein, "GAAP" refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company's historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core businesses. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our businesses by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

"EBITDA"- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

"Adjusted EBITDA"- is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses.

About the Linea DNA™ and Linea™ IVT Platforms

The Linea DNA platform is an entirely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs. The Linea IVT platform combines DNA IVT templates manufacturing via the Linea DNA platform with a proprietary Linea™ RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of double-stranded DNA (dsRNA) contamination; and 3) simplified mRNA production workflows.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, as of February 13, 2025, we operate in two primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.

Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding its belief that restructuring will position the company for future growth potential, its goal to position the company for long term-growth and value creation and the potential to achieve that goal, the future success of its Linea DNA and Linea IVT platforms and future reductions in operating expenses. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our Linea IVT and or Linea DNA platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or Linea IVT platforms, the unknown amount of revenues and profits that will result from its TR8 PGx testing service, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]

Web: www.adnas.com

X: @APDN

- Financial Tables Follow -

APPLIED DNA SCIENCES, INC.
CONSOLIDATED BALANCE SHEETS

December 31,

September 30,

2024

2024

ASSETS

(unaudited)

Current assets:
Cash and cash equivalents

$

9,294,365

$

6,431,095

Accounts receivable, net of allowance for credit losses of $82,723 and $75,000 at December 31, 2024, and September 30, 2024, respectively

911,502

362,013

Inventories

468,580

438,592

Prepaid expenses and other current assets

601,508

815,970

Total current assets

11,275,955

8,047,670

Property and equipment, net

638,483

553,233

Other assets:
Restricted cash

750,000

750,000

Intangible assets

2,698,975

2,698,975

Operating right of use asset

607,288

739,162

Total assets

$

15,970,701

$

12,789,040

LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued liabilities

$

1,610,972

$

1,793,427

Operating lease liability, current

558,426

545,912

Deferred revenue

217,215

58,785

Total current liabilities

2,386,613

2,398,124

Long term accrued liabilities

31,467

31,467

Deferred revenue, long term

194,000

194,000

Operating lease liability, long term

48,861

193,249

Deferred tax liability, net

684,115

684,115

Warrants classified as a liability

76,000

320,000

Total liabilities

3,421,056

3,820,955

Commitments and contingencies (Note G)
Applied DNA Sciences, Inc. stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2024, and September 30, 2024

-

-

Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2024, and September 30, 2024

-

-

Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2024, and September 30, 2024

-

-

Common stock, par value $0.001 per share; 200,000,000 shares authorized as of December 31, 2024 and September 30, 2024, 54,111,523 and 10,311,885 shares issued and outstanding as of December 31, 2024 and September 30, 2024, respectively

54,114

10,314

Additional paid in capital

339,918,754

318,805,058

Accumulated deficit

(327,219,390

)

(309,672,755

)

Applied DNA Sciences, Inc. stockholders' equity

12,753,478

9,142,617

Noncontrolling interest

(203,833

)

(174,532

)

Total equity

12,549,645

8,968,085

Total liabilities and equity

$

15,970,701

$

12,789,040

APPLIED DNA SCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

Three Months Ended December 31,

2024

2023

Revenues
Product revenues

$

495,847

$

307,317

Service revenues

374,444

247,147

Clinical laboratory service revenues

326,326

336,700

Total revenues

1,196,617

891,164

Cost of product revenues

264,052

282,545

Cost of clinical laboratory service revenues

248,458

377,522

Total cost of revenues

512,510

660,067

Gross profit

684,107

231,097

Operating expenses:
Selling, general and administrative

2,633,098

3,084,348

Research and development

1,015,010

935,815

Total operating expenses

3,648,108

4,020,163

LOSS FROM OPERATIONS

(2,964,001

)

(3,789,066

)

Interest income

71,440

33,323

Unrealized gain on change in fair value of warrants classified as a liability

244,000

2,639,000

Other expense, net

(20,152

)

(13,538

)

Loss before provision for income taxes

(2,668,713

)

(1,130,281

)

Provision for income taxes

-

-

NET LOSS

$

(2,668,713

)

$

(1,130,281

)

Less: Net loss attributable to noncontrolling interest

29,301

25,181

NET LOSS attributable to Applied DNA Sciences, Inc.

$

(2,639,412

)

$

(1,105,100

)

Deemed dividend related to warrant modifications

(14,907,223

)

(77,757

)

NET LOSS attributable to common stockholders

$

(17,456,635

)

$

(1,182,857

)

Net loss per share attributable to common stockholders-basic and diluted

$

(0.56

)

$

(1.73

)

Weighted average shares outstanding- basic and diluted

31,518,861

683,672

APPLIED DNA SCIENCES, INC.
CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA
(unaudited)

Three Month Period Ended December 31,

2024

2023

Net loss

$

(2,688,713

)

$

(1,130,281

)

Interest income

(71,440

)

(33,323,

)

Depreciation and amortization

58,580

298,951

Provision for bad debt

7,723

-

Stock based compensation expense

28,973

340,705

Unrealized gain on change in fair value of warrants classified as a liability

(244,000

)

(2,639,000

)

Total non-cash items

(220,164

)

127,062

Consolidated Adjusted EBITDA (loss)

$

(2,888,877

)

$

(3,162,948

)

###

SOURCE: Applied DNA Sciences, Inc.



View the original press release on ACCESS Newswire

J.Barnes--TFWP